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Introduction 
Recent advances in endovascular technology have 
generated a variety of alternative procedures and 
instruments in treating peripheral arterial occlusive 
disease. Mechanical atherectomy has been developed 
as an alternative to conventional percutaneous trans- 
luminal angioplasty (PTA) because of its limitations. 
Atherectomy devices can selectively remove atheroma 
by cutting or pulverising it in atherosclerotic diseased 
arteries percutaneously with angiographic guidance 
or openly through a small arteriotomy distant from 
the diseased site under fluoroscopic or angioscopic 
control. Theoreticall3~ atherectomy offers three advan- 
tages over PTA: (1) greater immediate success rate 
with lower rates of intimal dissection and acute 
occlusion due to the controlled removal of atheroma 
from the lumen; (2) wider application to complex 
lesions not readily amenable to PTA; and (3) reduction 
of restenosis rate due to the debulking of ather- 
omatous mass. 
There are currently two types of atherectomy 
devices: extirpative and ablative. Extirpative ather- 
ectomy is characterised by shaving, cutting, or directly 
removing atheroma nd collecting the excised mate- 
rial from the vessel umen and wall. Ablative ather- 
ectom~ on the other hang uses a high-speed rota- 
tional device to pulverise atheroma into fragments 
small enough to be aspirated or removed through the 
reticuloendothelial system. Among the numerous 
atherectomy devices currently available, only four 
have undergone xtensive clinical trials: the extirpa- 
tive catheters--the Simpson Atherocath and the 
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transluminal extraction catheter (TEC); and the abla- 
tive devices--the Trac-Wright catheter and the Auth 
Rotablator. Recently, a new directional atherectomy 
device, the Omnicath, has undergone clinical inves- 
tigative trials but only animal results have been 
published so far. 1 
Results 
Studies of the Simpson atherectomy device have 
reported impressively high initial success rates. 2-4 
Graor and Whitlow 2 reported a patency rate of 93% 
for lesions < 5 cm and 86% for lesions > 5 cm at I year. 
However, 2 year patency results of 42% and 35% 
reported by Lugmayr et al. 3 and Vroegindewij et al., 4 
respectively, are no better than those reported for 
PTA. 
The initial technical success and immediate clinical 
success rates of TEC atherectomy seem promising, but 
late follow-up has been either lacking or relatively 
short. Wholey and Jarmolowski 5 reported an impres- 
sive 92% technical success rate and a 90% dinical 
success rate. However, only 16 (17%) patients had 
undergone angiography at 6 months, 12 of whom 
revealed patent atherectomised lesions. Myers et al. 6 
obtained an initial technical success of 86% and a 
clinical success of 74% in treating stenotic and occlu- 
sive lesions. Primary patency rates at 6 months were 
80% for lesions < 5 cm and 64% for lesions > 5 cm. No 
long term patency results are available. 
The initial technical success rates of the Trac-Wright 
catheter have ranged widely from 58% to 100% and 
clinical success rates from 33% to 80%. 7-1° However, 
follow-up has shown suboptimal patencies ranging 
from 25% to 68% at 6 months and 25% to 45% at 12 
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months. One should also note that most of the clinical 
trials using the TEC and Trac-Wright catheters 
required adjunctive PTA to obtain an adequate arterial 
lumen since these catheters have no expansion ratio. 
Peripheral atherectomy with the Auth Rotablator 
has achieved promising initial technical and clinical 
success rates in several clinical trials. However, most 
series report only a short follow-up of 6 months and 
patencies during this time interval are poor ranging 
from 47% to 82%.1~-13 Furthermore, later patency at 1 
and 2 years is worse; the Collaborative Rotablator 
Atherectomy Group (CRAG) reported a disappointing 
patency of 31% at 1 year and 18.6% at 2 yearsJ 2 
months, Myers et al. 6 reported restenosis n 26 lesions 
(18%) and reocclusion in 51 (35%) with the TEC. 
Reocclusion also limits the applicability of the Trac- 
Wright catheter: Wholey et al. reported 4/12 early 
reocclusions (33%); Desbrosses et aI. s reported 5/46 
reocclusions (11%) within 48 h; and Lukes et al. 9 
reported 2/12 reocclusions (17%). Late restenoses and 
reocclusions also occurred in 32 limbs during a follow- 
12 up period of 15-41 months by the CRAG. Thus, 
contrary to initial expectations, debulking atheroma 
does not reduce or solve PTA's main problem, reste- 
nosis and reocclusion. 
Complications 
Major complications of peripheral atherectomy 
devices include dissection, distal embolisation, hae- 
matoma, perforation, and thrombosis. With the Simp- 
son device, Graor and Whitlow 2 reported seven cases 
of haematoma that required major intervention, 
including one patient who also developed a pseudo- 
aneurysm. The TEC device, on the other hand, have 
caused various complications; Myers et al. 6 reported 
two deaths (1%) in patients with critical ischaemia, 
fracture of catheters requiring removal and replace- 
ment in two (1%), thromboembolism in two (1%), and 
bleeding at the puncture site in three (2%) within 30 
days. In contradistinction to previous studies, ~4 the 
dissections and perforations encountered by some of 
the investigators 3,8,12,13 suggest hat the arterial wall 
did not always remain intact. Desbrosses et al. 
reported that perforation i duced by the rotating cam 
of the Trac-Wright catheter occurred mostly in heavily 
calcified lesions due to the catheter's tendency to 
follow the path of least resistance, which is often away 
from hard calcified plaque, s Distal embolisations 
caused by atherectomy devices have been docu- 
mented by some investigators. 5'9'~'13 Contrary to 
~4 previous canine studies, the CRAG 12 and Henry et 
al. 13 demonstrated that some of the atherectomised 
particles generated by the Auth Rotablator can cause 
embolic omplications. Furthermore, the CRAG 12 and 
Henry et al. ~3 reported nine (11%) and 12 (8%) early 
thromboses, respectively. 
Limitations 
Similar to PTA, restenosis and reocclusion are the 
primary constraints of atherectomy devices. At 6 
Discussion 
Each atherectomy device has been designed to address 
restenosis, reocclusion, and other problems that 
frequently plague the results of PTA. Each one has 
utilised remarkable technology to produce the 
aesthetic result of a smooth lumen without flaps, 
dissections, perforations, or other abnormalities and 
consequently reduce the likelihood of thromboemboli- 
sation, restenosis, and reocclusion. The Simpson 
AtheroCath has a retrieval chamber to collect the 
excised plaque; the TEC utilises a suction to aspirate 
the debris; the Trac-Wright catheter has a high speed 
rotating cam to micropulverise atheroma without 
damaging the arterial wall; the Auth Rotablator uses a 
high speed rotating burr to micropulverise hard 
calcified atheroma; nd the OmniCath uses an anchor- 
ing deflector wire pad to prevent vessel wall injury 
and neointimal proliferation. 
A review of the clinical investigations utilising 
atherectomy devices clearly establishes the feasibility 
of peripheral atherectomy in the treatment of arterial 
occlusive disease. However, inspite of the impressive 
and appealing technology ofthese devises, the efficacy 
of atherectomy remains questionable. Furthermore, 
none of the devices fulfill the aforementioned xpecta- 
tions without complications. Moreover, although the 
initial technical and clinical patencies are promising, 
intermediate and long-term patencies are either sim- 
ilar or perhaps even worse than those of PTA. 
Inconsistencies in reporting endovascular proce- 
dures plague most of the clinical data available in the 
literature. Discrepancies in reporting clinical and 
haemodynamic assessment, description of lesions, 
various criteria in reporting early and continued 
success (short vs. intermediate vs. long-term follow- 
up), complications, and the comparison of different 
treatment modalities make it difficult, if not impos- 
sible, to precisely evaluate the efficacy of atherectomy 
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devices. Thus, the comparison of these inaccurate 
results with those of other treatment modalities uch 
as PTA is invalid. In reporting endovascular proce- 
dures, clinical investigators should refer and follow 
the guidelines described in detail by the Ad Hoc 
Subcommittee on Reporting Standards for Endovas- 
cular Procedures. i  
Peripheral atherectomy currently has limited appli- 
cations in the treatment of arterial occlusive disease. 
The problem of restenosis, reocclusion, and other 
complications must be solved before atherectomy 
devices can be used generally as an alternative to 
standard vascular econstruction procedures or PTA. 
These problems can be solved only by addressing 
technological, mechanical, and biological factors in a 
rigorously scientific manner. 
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